Hypothalamic neuropeptides play essential roles in regulating energy and body weight balance. Energy imbalance and obesity have been linked to hypothalamic signaling defects in regulating neuropeptide genes; however, it is unknown whether dysregulation of neuropeptide exocytosis could be critically involved. This study discovered that synaptotagmin-4, an atypical modulator of synaptic exocytosis, is expressed most abundantly in oxytocin neurons of the hypothalamus. Synaptotagmin-4 negatively regulates oxytocin exocytosis, and dietary obesity is associated with increased vesicle binding of synaptotagmin-4 and thus enhanced negative regulation of oxytocin release. Overexpressing synaptotagmin-4 in hypothalamic oxytocin neurons and centrally antagonizing oxytocin in mice are similarly obesogenic. Synaptotagmin-4 inhibition prevents against dietary obesity by normalizing oxytocin release and energy balance under chronic nutritional excess. In conclusion, the negative regulation of synaptotagmin-4 on oxytocin release represents a hypothalamic basis of neuropeptide exocytosis in controlling obesity and related diseases.
INTRODUCTION
The hypothalamus in the central nervous system (CNS) is known as the central regulator of feeding, energy, and body weight homeostasis (Coll et al., 2007; Flier and Maratos-Flier, 1998; Mobbs, 2007; Park and Bloom, 2005; Schwartz et al., 2000; Ukropec et al., 2006) . All these hypothalamic functions are critically mediated by various hypothalamic neuropeptides. Several wellappreciated examples of such neuropeptides include a-melanocyte stimulating hormone (a-MSH), cocaine and amphetamine regulated transcript (CART), neuropeptide Y (NPY), and agoutirelated peptide (AGRP). These neuropeptides have been shown to be controlled at the gene transcriptional levels (Bates et al., 2003; Kim et al., 2006; Kitamura et al., 2006; Xu et al., 2005) by nuclear transcription factors that sense nutrient and metabolic cues of the body (Ahima et al., 1996; Air et al., 2002; Friedman and Halaas, 1998) . Interestingly, recent research has begun to recognize the importance of neuropeptide posttranscriptional modulation (Plum et al., 2009) , indicating that the control of neuropeptide gene expression represents only an initial step in the whole cascade of neuropeptide regulation. Logically, this process ultimately involves regulation of neuropeptide release to precisely control the biological functions of neuropeptides. However, how hypothalamic neuropeptide exocytosis is regulated and whether it is critical for metabolic physiology and disease have not been explored.
Recent research in basic science has obtained significant knowledge regarding the general principles of neuropeptide/ neurotransmitter vesicular exocytosis (Stojilkovic, 2005) . Studies based on synaptic neurotransmitter release have identified vesicular exocytosis as a process that is mediated by soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNARE) complex (Jahn and Scheller, 2006; Sü dhof and Rothman, 2009) under the regulation of synaptotagmins (Syts) (Chapman, 2008; Sü dhof, 2002) . Syts are a group of Ca 2+ -binding proteins that catalyze the formation of SNARE complex to provide the force and energy required for exocytosis. The mammalian Syt family is composed of 17 members. While most of them are predominantly present in the CNS, some of them are involved in the vesicular functions of endocrine cells such as pancreatic a and b cells (Fukuda and Mikoshiba, 1999; Gao et al., 2000; Iezzi et al., 2005) and glucose-transport metabolic cells (Hudson and Birnbaum, 1995; Li et al., 2007) . These interesting studies, which were mainly based on peripheral endocrine systems, have raised the recent alarm on the potential implication of Syts in diabetes . However, research to date addressing Syts in hypothalamic neuroendocrine neurons is still missing.
Syt4 is an inducible Syt isoform detectable only in the brain and in the neuroendocrine system (Vician et al., 1995) , hinting at a possible role in neuroendocrine physiology. Notably, compared to other Syt family members, the puzzling aspect of Syt4 is its lack of a critical Ca 2+ -binding amino acid (von Poser et al., 1997) and related inability to induce Ca 2+ -dependent exocytosis in biophysical models (Chapman et al., 1998; Thomas et al., 1999) . Recent biophysical research reported that Syt4 inhibits exocytotic activities in the posterior pituitary (Zhang et al., 2009 ) and in cultured PC12 cells (Machado et al., 2004) , suggesting a potential neuroendocrine role of Syt4. In this research, through targeting the regulators of vesicle exocytosis including SNARE complex proteins and Syt family members, we identified a hypothalamic program of oxytocin (OXT) release regulated by Syt4 and established the physiological significance of this regulation in the hypothalamic control of energy balance and related diseases.
RESULTS

Abundant Distribution of Syt4 in the Hypothalamic Paraventricular Nucleus
The hypothalamus regulates energy balance essentially through neuropeptide release. Therefore, we explored whether the hypothalamus has a regulatory program for neuropeptide release that is critical for metabolic physiology, and whether alteration of this program causes metabolic disease. We adopted a candidate screening strategy by targeting neuropeptide release regulators, including SNARE complex proteins and Syt family proteins in the hypothalamus. Western blots initially confirmed that Syt4 was detectable in the brain and the posterior pituitary, but not in the peripheral tissues. Immunostaining further revealed that Syt4 was expressed abundantly in a subpopulation of cells in the paraventricular nucleus (PVN) ( Figure 1A ) and the supraoptic nucleus of the hypothalamus, but only modestly in a few other brain regions such as hippocampus and the cortex (data not shown). The specificity of Syt4 antibody (Zhang et al., 2009 ) was verified by western blot and immunostaining analyses of hypothalamic samples from Syt4 knockout (Syt4 À/À ) mice (Ferguson et al., 2000a ) (Figures S1A-S1C available online). In addition, both mRNA in situ hybridization ( Figure S1D ) and real-time RT-PCR ( Figure S1E ) confirmed that Syt4 expression was uniquely enriched in the hypothalamus. High-magnification images of Syt4 immunostaining ( Figure 1A ) revealed that Syt4 was present in the cell bodies and projections of a subpopulation of cells with neuronal morphology in the PVN. Subsequent coimmunostaining of Syt4 with NeuN (a neuronal marker) confirmed that Syt4 was exclusively expressed in neurons, but not other cell types (Figure 1B) . High-resolution images of coimmunostaining revealed that Syt4 colocalized with vesicle-like structures in the cytoplasm and projections of neurons (Figure 1B, inserts) . In support of this observation, Syt4 immunogold labeling and electron microscopy analysis showed that Syt4 was abundantly localized in vesicles of a subpopulation of PVN neurons ( Figure 1C ) and in axonal terminals of the PVN neurons that projected into the posterior pituitary ( Figure 1D ). Thus, in line with a previous report that Syt4 is present only in the brain and neuroendocrine system (Vician et al., 1995) , our data revealed that Syt4 is abundantly expressed in a specific subtype of PVN neurons, which may indicate a previously unappreciated role of Syt4 in hypothalamic control of physiology.
Nutritional Excess Promotes Syt4 Expression and Vesicular Localization
Since the PVN is one of the hypothalamic regions that critically regulate energy and metabolic balance, we subsequently explored whether nutritional excess could affect the expression and vesicular profiles of Syt4 in the hypothalamus-pituitary axis. First, quantitative real-time RT-PCR was used to measure Syt4 mRNA levels in the hypothalamus of C57BL/6 mice that were chronically maintained on a normal chow diet versus a high-fat diet (HFD). Results showed that HFD feeding increased Syt4 mRNA levels in the hypothalamus, but not in other brain regions All experimental mice were adult males, chow-fed, and in the C57BL/6 background. AMY, amygdala; COR, cortex; LH, lateral hypothalamus; OP, optic tract; PVN, paraventricular nucleus; PP, posterior pituitary; TH, thalamus; 3V, third ventricle.
( Figure S1E ), suggesting that Syt4-directed vesicular exocytosis could be involved in the hypothalamic control of HFD-induced metabolic disorders. To further evaluate this possibility, Syt4 immunogold labeling and electron microscopy were employed to examine whether HFD feeding could affect vesicular localization of Syt4 in PVN neurons. Results showed that HFD feeding nearly doubled the number of vesicle-bound Syt4 particles in PVN dendrites and axonal terminals (Figures S1F and S1G). Thus, obesity development under nutritional excess is associated with hypothalamic changes of Syt4 expression and in particular Syt4 vesicular distribution.
Syt4 Inhibition Prevents Obesity by Normalizing Energy
Balance Syt4 À/À mice were then employed to test if Syt4 ablation could affect obesity and related metabolic diseases. Based on our observation as well as the literature (Vician et al., 1995) Figure 2A ) despite slightly reduced food intake ( Figure 2B ) and evidently increased energy expenditure ( Figure 2C ). On the other hand, a long-term follow-up revealed that Syt4 À/À mice were completely protected from the development of postadult weight gain ( Figures S2A and S2B) . Therefore, the catabolic effects of Syt4 ablation on body weight were accumulative and required an adequate age to manifest. Taken together, Syt4 inhibition is catabolic; while its impact on body weight is minor at young ages, it can provide accumulative benefits against age-related fat expansion and weight gain at postadult ages. To better elucidate the potential antiobesity effect of Syt4 ablation, the paradigm of HFD feeding was applied to Syt4 À/À mice and WT littermate controls after weaning. Data revealed that while WT controls developed profound obesity over a 6 month period, mice was due to the resistance to fat mass expansion without loss of lean body mass. Daily HFD intake of these mice was longitudinally monitored, revealing that Syt4 À/À mice consumed a reduced amount of HFD compared with WT mice ( Figure 2B ). Indirect calorimetry was applied to Syt4 À/À and WT mice during the initial stage ($1-2 weeks) of HFD feeding when mice of both groups still had comparable body weight. Syt4 À/À mice, upon switching to an HFD, had higher energy expenditure levels than matched WT mice (data not shown), which was similar to the energy expenditure pattern under the normal chow feeding condition ( Figure 2C ). To further assess whether increased energy expenditure contributed to the antiobesity phenotype of Syt4 À/À mice, HFD pair feeding was provided to adult Syt4 À/À and WT mice. Although the total calories provided through HFD pair feeding were reduced compared with ad libitum feeding, adult (A-E) Syt4 À/À mice (blue and green curves/bars) and WT littermate controls (black and red curves /bars) were maintained on a chow (black and blue curves/bars) versus an HFD (red and green curves/bars) since weaning. At 4 months of age, mice were analyzed with the glucose tolerance test (GTT) (A and B), and random blood glucose levels (C), and fasting blood insulin (D) and leptin (E) levels were also analyzed. AUC, area under curve of GTT. *p < 0.05, **p < 0.01, n = 5-7 per group.
(F and G) Syt4 À/À mice and WT littermate controls were maintained on an HFD for 4 months since weaning. Pancreases were collected and sectioned for H&E staining (F) and coimmunostaining of insulin (green) and glucagon (red) (G). Scale bar = 100 mm. Data presented were based on male mice but representatives of both sexes. Error bars reflect mean ± SEM.
WT mice still gained weight over a 4 week period-an outcome of impaired energy expenditure resulting from HFD-associated malnutrition. In contrast, a significantly smaller magnitude of weight gain was observed in Syt4 À/À mice under the same HFD feeding regime ( Figure 2E ), and such weight gain reduction can be attributed to elevated energy expenditure induced by Syt4 ablation. Finally, we explored whether obesity development could be acutely attenuated by Syt4 ablation through the control of energy expenditure in addition to food intake. HFD-fed C57BL/6 mice received bilateral intra-PVN injections of Syt4 shRNA lentiviruses or control lentiviruses (Figures 2F and 2G). HFD pair feeding was then provided to both groups after injection ( Figure S2I ). Compared with the control mice, Syt4 shRNA-injected mice had higher energy expenditure levels at week 1 postinjection ( Figure 2H ), a time point when body weights of both groups were still comparable. Further followup revealed that Syt4 shRNA-injected mice gained less body weight than control mice (Figures 2I and S2J) . Such an antiweight gain effect of Syt4 ablation can be specifically related to increased energy expenditure, since HFD intake was controlled at the same level via pair feeding. Therefore, in conjunction with the food intake data in Figure 2B , it can be concluded that the antiobesity effect of Syt4 inhibition under nutritional excess is mediated by both energy expenditure increase and energy (food) intake restriction.
Syt4 Inhibition Prevents against Obesity Comorbidities
The frequent disease consequences of obesity include glucose intolerance, insulin resistance, and tissue lipid infiltrations. In the context of Syt4's relevance to obesity, we additionally assessed whether Syt4 inhibition was sufficient to prevent against obesity-associated diseases. Under HFD feeding, WT mice developed severe glucose intolerance (Figures 3A and 3B) and slight hyperglycemia ( Figure 3C ); in contrast, Syt4 À/À mice were completely normal. Consistent with these metabolic profiles, HFD-treated WT mice, but not Syt4 À/À mice, developed profound insulin resistance and leptin resistance, presented in the forms of hyperinsulinemia ( Figure 3D ), hyperleptinemia (Figure 3E) , and pancreatic islet hypertrophy ( Figure 3F ). Double immunostaining of insulin and glucagon in pancreatic sections confirmed that pancreatic islets of HFD-treated WT mice displayed centralization of glucagon-producing cells, a morphological indicator of islet damage, but such pathologic changes were not seen in HFD-treated Syt4 À/À mice ( Figure 3G ). Finally, the mice were assessed for lipid infiltration profiles in the liver and skeletal muscles. HFD-treated WT mice showed severe hepatic steatosis ( Figure S3A ) and muscular lipid deposits ( Figure S3B ); in contrast, HFD-treated Syt4 À/À mice were completely or significantly protected from developing these lipid abnormalities. All these metabolic benefits to Syt4 À/À mice were predicted to be mainly secondary to obesity prevention, but it is also possible that Syt4 ablation may directly improve obesity-related glucose and lipid homeostasis.
Colocalization of Syt4 and OXT in the PVN Neurons Next our study aimed to understand which neuropeptide or neuropeptides were directed by hypothalamic Syt4 to account (C) OXT and Syt4 coimmunogold labeling in OXT versus AVP axonal terminals. The posterior pituitaries from normal C57BL/6 mice were sectioned and coimmunogold-labeled with OXT (small particles) and Syt4 (large particles). The image represents a junction region that contains both OXT axonal terminals and AVP axonal terminals (separated by a blue dotted line). Red arrows indicate dense-core vesicles, and green arrows indicate microvesicles. Scale bar = 100 nm. All experimental mice were adult males, chow-fed, and in the C57BL/6 background.
for the physiological effects of Syt4 knockout. Since Syt4 is abundantly expressed in the PVN neurons (Figure 1) , and PVN importantly integrates many other hypothalamic nuclei to control energy balance, we focused our study on this hypothalamic site. Coimmunostaining of Syt4 with various PVN neuropeptides revealed that Syt4 was enriched in OXT-expressing neurons in the PVN ( Figure 4A , upper panels). For comparison, PVN sections were coimmunostained for Syt4 and arginine vasopressin (AVP), a neuropeptide structurally closely related to OXT. Surprisingly, Syt4 was undetectable in the majority of AVP neurons except for a few that coexpressed OXT and AVP ( Figure 4A , lower panels). These results indicate that OXT and AVP probably employ different Syt-directed regulatory systems to control their exocytosis, and such a difference may form a basis for their different physiological functions.
Subsequently, high-magnification imaging of Syt4 and OXT coimmunostaining was used to examine the morphology of Syt4-containing subcellular structures in detail. As shown in Figure 4B , the subcellular organelles recognized by Syt4 immunostaining displayed the appearance of aggregated vesicles that were also encompassed by OXT, suggesting that Syt4 is physically present in OXT vesicles. To prove this hypothesis, immunogold colabeling of Syt4 with OXT and electron microscopy analysis were performed, and data confirmed that Syt4 was selectively present in the dendritic and axonal vesicles of OXT neurons ( Figure 4C ). In comparison, Syt4-positive vesicles were not detected in adjacent AVP neurons ( Figure 4C ). In addition to the dense-core vesicles, Syt4 particles appeared to be modestly present in microvesicles, suggesting that regulation of neurotransmitter release by Syt4 in these neurons is also possible. Overall, Syt4 is expressed specifically in OXT neurons and might critically regulate OXT release to modulate the biological functions of hypothalamic OXT.
Syt4 in OXT Neurons Mediates Metabolic Actions
The connection between Syt4 and OXT prompted further investigation of whether Syt4 acts in OXT neurons to mediate the antiobesity benefit of Syt4 À/À mice. To do so, we examined whether an exogenous induction of Syt4 in OXT neurons within the PVN could recapitulate the effects of HFD feeding to cause weight gain. OXT gene promoter (Zhang et al., 2002 ) was used to generate OXT neuron-specific Syt4 or control (GFP) lentiviruses. The cell specificity of these lentiviruses was verified by examining the PVN of virus-injected mice ( Figures 5A and 5B ). As expected, delivery of Syt4 into OXT neurons within the PVN mimicked HFD feeding to promote food intake ( Figure 5C ) and weight gain ( Figures 5D and 5E ) in C57BL/6 mice despite normal chow feeding condition. Importantly, both effects were abolished by daily OXT injections via the third ventricle ( Figures 5C  and 5D ), indicating that OXT in the brain can antagonize the metabolic action of Syt4. In parallel, we examined whether the antiobesity phenotype of Syt4 À/À mice could be reversed by restoring Syt4 in OXT neurons. OXT neuron-specific Syt4 or control GFP lentiviruses were injected into the PVN of HFD-fed analysis revealed a 42% restoration of Syt4 mRNA in the PVN of Syt4 À/À mice ( Figure 5F ). Longitudinal food intake and body weight monitoring indicated that the delivery of Syt4 significantly abrogated the antiobesity phenotype of Syt4 À/À mice (Figure 5G) , and these mice regained hyperphagia (Figure 5H ). The reversal of metabolic changes was partial, which might be related to the technical limitation of a viral injection approach, or it might point to the possibility that other neurons in the brain also contribute to the metabolic phenotype of Syt4 À/À mice. Altogether, based on the gain-of-function study using conventional C57BL/6 mice and the rescue experiment using Syt4 À/À mice, it can be concluded that OXT neurons are important for the metabolic effects of Syt4.
Syt4 Negatively Regulates OXT Release in the PVN
Following the above physiological studies, we aimed to investigate if and how Syt4 can regulate OXT exocytosis. Experiments were designed to test the effects of Syt4 loss of function on OXT release via OXT ex vivo release assay, an established method to study OXT release in the PVN (Jin et al., 2007; Sladek and Somponpun, 2008) . Live PVN slices from the hypothalamus of chowfed Syt4 À/À mice or WT controls were used for OXT release measurement. Results revealed that Syt4 ablation significantly enhanced OXT release in the PVN slices under both basal and KCl-depolarized conditions ( Figure 6A ). This finding was confirmed by an independent assay that analyzed the 60 min dynamics of OXT release in the PVN tissues from Syt4 À/À versus WT mice ( Figures S4A and S4B ). Hypothalamic OXT mRNA levels were comparable between chow-fed Syt4 À/À and WT mice ( Figure S5A ), which excluded the involvement of OXT gene expression. These data indicate that Syt4 negatively regulates OXT exocytosis, which is supported by the inhibitory structural (Chapman et al., 1998; Thomas et al., 1999) and biophysical (Zhang et al., 2009 ) characteristics of Syt4. We further inferred that the blood OXT levels should be higher in Syt4 À/À mice than in WT controls regardless of dietary conditions. Measurements of circulating OXT levels in Syt4 À/À and WT mice on either a normal chow or an HFD confirmed this prediction ( Figure 6B ). We also measured hypothalamic OXT mRNA levels of HFD-fed Syt4 À/À and WT mice. Compared with chow feeding, HFD
enhanced OXT mRNA levels in WT mice ( Figure S5A ), which was likely a compensatory response to suppressed OXT release under HFD. In contrast, hypothalamic OXT mRNA levels were comparable between HFD-fed and chow-fed Syt4 À/À mice (Figure S5A) , indirectly indicating that HFD-fed Syt4 À/À mice did not suffer OXT release impairment. To summarize, exocytosis, but not gene expression, of OXT is negatively regulated by Syt4.
Brain OXT Restricts Food Intake and Promotes Energy Expenditure
OXT is a hypothalamic neuropeptide that is synthesized by OXT neurons and released from both axon terminals and somatodendritic regions. In addition to its classical role in reproductive physiology, OXT also regulates various social behaviors such as care, love, emotion, and trust (Ferguson et al., 2000b; Keverne and Curley, 2004; Kosfeld et al., 2005) . Of note, many of these classical and nonclassical actions of OXT were associated with feeding changes (Douglas et al., 2007; Leng et al., 2008 ). More recently, genetic studies reported that hyperphagia and obesity developed in mice that were genetically deficient in OXT (Amico et al., 2005; Kublaoui et al., 2008) or OXT receptor . While these genetic approaches targeted the whole body, the brain-specific role of OXT in metabolic physiology has not yet been defined. To study the central action of OXT, we injected OXT into the brains of normal C57BL/6 mice via third ventricle cannula. Central administration of OXT readily suppressed food intake ( Figure 6C ) and elevated energy expenditure ( Figure 6D ). Importantly, brain injection of OXT did not yield side effects on the general health, as confirmed by multiple behavioral tests including kaolin intake test ( Figure S5B ), conditioned taste aversion test ( Figure S5C ), elevated plus maze (Figure S5D-S5F) , and open field test ( Figure S5G ). In conclusion, OXT in the brain can exert a catabolic regulatory effect on energy balance by restricting food intake and promoting energy expenditure.
Obesity Is Associated with Impaired OXT Release
Following the observations that HFD-induced obesity is associated with increased hypothalamic Syt4 mRNA levels and Syt4 vesicular distribution (Figures S1E-S1G), we predicted that dietary obesity might be causally related to altered OXT release. This hypothesis was also suggested by the data in Figure 6B showing that circulating levels of OXT in HFD-fed mice were reduced by $40% compared with those of chow-fed mice. To test this hypothesis, we employed an ex vivo OXT release assay to determine if HFD feeding could affect OXT release of the hypothalamic PVN. KCl-induced depolarization elicited an OXT release response in the PVN slices of chow-fed WT mice (Figure 6A ), but this effect was blunted by HFD feeding ( Figure 6E , left panel). In contrast, HFD did not blunt depolarization-induced OXT release in the PVN slices of Syt4 À/À mice ( Figure 6E , left Figure 6E , right panel, and Figure 6F ). In sum, while obesity causes impaired OXT release of the PVN, the antiobesity phenotype of Syt4 À/À mice is associated with retained sensitivity of OXT release.
Obesogenic Effects of OXT Antagonists in WT and Syt4 -/-Mice
To further analyze the significance of the hypothalamic Syt4-OXT pathway in obesity development, we examined whether OXT antagonists could be obesogenic. First, a pharmacological approach was employed by daily injections of OVT (an OXT antagonist) into the third ventricle of WT and Syt4 À/À mice under a chow or HFD feeding condition. Compared with vehicle injections, OVT increased food intake in chow-fed WT and Syt4 À/À mice ( Figure 7A ), resulting in increased weight gain over a 2 week follow-up period ( Figure 7B ). Similarly, OVT increased food intake in HFD-fed WT and Syt4 À/À mice ( Figure 7C ). As a result, the effect of HFD in promoting weight gain was exacerbated in WT mice, and the antiobesity phenotype in HFD-fed for 3 months since weaning, and were subsequently implanted with cannula into the third ventricle. After 2 weeks of postoperative recovery, mice received daily third ventricle injections of OVT (4 mg) versus vehicle (Veh) for 2 weeks, and were monitored for daily 12 hr daytime food intake after injection (A and C) and weekly body weight (BW) gain (B and D) during the 2 week treatment period. *p < 0.05, n = 5-6 per group. Mice in all these experiments were males. (E-J) Syt4 À/À mice and WT littermate controls were maintained on a normal chow (E-H) versus an HFD (I and J) for 5 months since weaning, and subsequently received bilateral intra-PVN injection of OXT shRNA (OXT-s) lentiviruses or control shRNA (Ctr-s) lentiviruses. (E and F) Lentivirus-mediated OXT ablation was assessed by OXT immunostaining (E, upper panels) and quantitated by counting OXT-expressing neurons in the serial PVN sections (F). AVP immunostaining of matched PVN sections (E, lower panels) was used as a control. 3V: third ventricle; scale bar = 50 mm. (G-J) Mice were monitored for daily food intake (G and I) and weekly BW gain (H and J) during a 3 week follow-up. *p < 0.05, n = 4-7 per group. Mice in all these experiments were males. Error bars reflect mean ± SEM.
Syt4
À/À mice was significantly abrogated (Figure 7D) . Next, OXT shRNA lentivirus was used to evaluate the Syt4-OXT connection in the brain control of feeding and body weight. Syt4 À/À mice and WT controls, maintained on either chow or HFD feeding, received bilateral intra-PVN injections of OXT shRNA lentiviruses or control lentiviruses. Immunostaining confirmed that OXT shRNA delivery sufficiently ablated the expression of OXT, but not the control neuropeptide AVP, in the PVN (Figures 7E and 7F ). As shown in Figures 7G-7J , shRNAmediated OXT ablation increased food intake and weight gain similarly in WT mice and Syt4 À/À mice under either chow or HFD condition. Compared with OVT injection, the obesogenic effects of OXT shRNA were stronger, consistent with the observation that OXT shRNA affected 24 hr food intake while the effect of OVT injection lasted only $12 hr after injection. In summary, results from both pharmacological and shRNA lentiviral injection experiments indicate that OXT critically mediates the role of Syt4 in hypothalamic control of weight gain and obesity.
Therapeutic Potential of OXT in Preventing Obesity
The overall results in Figures 1-7 demonstrated that chronic nutritional excess can promote hypothalamic Syt4 to suppress OXT release, leading to energy imbalance and obesity. Following these findings, we explored the therapeutic relevance of this conceptual model by testing if central administration of OXT could treat dietary obesity in mice. C57BL/6 mice were first allowed to develop obesity via 5 month HFD feeding, and were subsequently implanted with third ventricle cannula. Following postsurgical recovery, mice received daily ICV injections of OXT or vehicle control for a period of 2 weeks. Injections were given every night before the light was off so that the duration ($4 hr) of OXT action overlapped the peak food-consuming period ($6 hr) of mice. Data revealed that OXT treatment rapidly reduced the magnitude of obesity during the first 3 days of the treatment and subsequently prevented HFD from causing weight gain ( Figure 7A ). Comparatively, we assessed whether OXT treatment might affect the body weight of chow-fed micewhich is mainly composed of lean body mass. Three days of OXT injections were found to only slightly reduce the body weight of chow-fed mice, while the same treatment had a more evident antiobesity effect in age-and sex-matched HFD-fed mice ( Figure S5H ). Thus, OXT has a strong antiobesity effect, but its impact on lean body mass was minimal, highlighting the potential value of OXT analogs in obesity treatment.
To summarize this study, Syt4-directed OXT release in the hypothalamus is critical for obesity development ( Figure 8B ), and Syt4 inhibitors or OXT analogs bear clinical potentials for treating obesity and related health problems.
DISCUSSION Neuropeptide Exocytosis in Hypothalamic Control of Energy Balance
The CNS regulates whole-body energy balance primarily via the mediobasal region and the PVN of the hypothalamus (Elmquist and Flier, 2004; Schwartz and Porte, 2005) . Recent research advances have significantly elucidated the neuronal subtypes and molecular pathways in these hypothalamic regions that direct the central control of feeding and energy expenditure (Balthasar et al., 2005; Bouret et al., 2004; Cone, 2005; Cowley et al., 2001; Elmquist and Flier, 2004) . The underlying molecular basis involves transcriptional regulation of neuropeptide genes in response to dynamic changes of the body's energy status (Brü ning et al., 2000; Coll et al., 2007; Cota et al., 2006; Flier and Maratos-Flier, 1998; Friedman and Halaas, 1998; Minokoshi et al., 2004; Mobbs, 2007; Mü nzberg and Myers, 2005; Park and Bloom, 2005; Schwartz et al., 2000) . However, compared with the appreciated neuropeptide gene regulation, the role of neuropeptide exocytotic regulation in metabolic actions remains unexplored, despite recent basic research advances showing that neuropeptide release from secretory granules is a cellular event with sophisticated regulation (Stojilkovic, 2005) . The present work discovered that exocytosis regulator Syt4 is expressed predominantly in a neuronal subtype of hypothalamic PVN, OXT neurons. Moreover, Syt4 is revealed to negatively regulate OXT release from OXT neurons. The physiological role of this negative regulation by hypothalamic Syt4 is anabolic, and under the environment of chronic nutritional excess, this Syt4 program is further enhanced by an unidentified mechanism or mechanisms to become obesogenic. While forcefully suppressing this Syt4 program does not evidently impact normal body weight homeostasis-which might be due to rebalance by other anabolic/catabolic systems-it provides a remarkable and nearly complete protection against the development of obesity and various other metabolic diseases under nutritional excess. These findings suggest that the significance of hypothalamic neuropeptide exocytotic regulation in obesity development and control is substantial. Along this line, further research is needed to explore the exocytotic regulations of other hypothalamic neuropeptides/neurotransmitters and the implications of these potential regulations in hypothalamic control of physiology and disease.
Inhibitory Regulation of Syt4 on OXT Exocytosis
The identification of the hypothalamic Syt4-OXT pathway by this work can provide an answer to the question regarding the physiological function of Syt4. Unlike other Syt members, Syt4 contains an atypical C2A domain in a midacid sequence (von Poser et al., 1997) and fails to catalyze the Ca 2+ -dependent exocytosis (Chapman et al., 1998; Thomas et al., 1999) . The physiological relevance of Syt4 became more puzzling with the relatively normal phenotype of Syt4 À/À mice under normal feeding condition (Ferguson et al., 2000a) , calling into question whether Syt4 can really regulate vesicle exocytosis in vivo. A recent electrophysiological study pointed to the neuroendocrinic relevance of Syt4 (Zhang et al., 2009) ; however, it offered only a biophysical characterization rather than a physiological study of Syt4 function in neuroendocrine and related diseases.
Chronic Challenge of Nutritional Excess
In the current work, we obtained results establishing Syt4 as an important negative regulator of OXT exocytosis in the hypothalamic neuroendocrine system. Considering that Syt4 is present not only in dense-core vesicles but also in microvesicles, we speculate that Syt4 may also contribute to the regulation of neurotransmitter release. While such a possibility was not examined in the current study, it represents an interesting subject for the next-step investigation. Other immediate questions stemming from the current research include whether and how other Syt members might be involved in the hypothalamic control of neuropeptide/neurotransmitter release to direct metabolic physiology and disease. Studies toward understanding these questions could form an interesting research area that addresses the role of vesicular exocytosis in the hypothalamic control of endocrine and metabolic physiology.
Central Actions of OXT in Controlling Energy Balance OXT, a hypothalamic neuropeptide known for its role in mediating reproductive activities, is synthesized by neurons that are localized predominantly in the PVN of the hypothalamus. OXT is released on demand to the blood stream from neuronal axon terminals that innervate the posterior pituitary. Recent attention has been drawn to OXT's role in regulating social behaviors, including care, love, emotion, and trust (Ferguson et al., 2000b; Keverne and Curley, 2004; Kosfeld et al., 2005) , and local release of OXT in the brain seems to underlie these regulations (Ludwig et al., 2002; Ludwig and Leng, 2006) . In addition, OXT has catabolic effects through suppressing food intake and promoting physical activities (Douglas et al., 2007; Leng et al., 2008) . More recently, several genetic studies reported the development of overeating and obesity in mice that were deficient in OXT (Amico et al., 2005; Kublaoui et al., 2008) or OXT receptor . The current research focused on OXT exocytosis regulation and provided evidence supporting the notion that regulation of OXT's local release is critical for hypothalamic control of energy and body weight balance. This concept is in line with recent literature that linked OXT to the hypothalamic actions of leptin (Kutlu et al., 2010) and nesfatin (Maejima et al., 2009) . Moreover, our research revealed a reverse relationship between OXT and feeding, i.e., excessive nutrient intake through HFD feeding suppresses OXT release. This observation is supported by a recent study showing that chronic sugar intake dampened the feeding-related c-Fos expression (an indicator of neuronal activities) in OXT neurons (Mitra et al., 2010) . Therefore, compromised action of OXT represents a significant hypothalamic mechanism for the development of dietary obesity and comorbidities. In addition to the mechanistic understanding, our experiments further confirmed that brain injection of OXT was effective in treating mouse obesity without causing appreciable nonspecific or side effects. However, given that OXT has a short half-life, the use of OXT for human obesity treatment remains challenging until appropriate OXT analogs and practical delivery methods can be developed.
Syt4: A Potential Antiobesity Target
The hypothalamus has been known as a pathogenic culprit for overeating, obesity, and related diseases. The underlying molecular mechanisms have been related to hypothalamic leptin and insulin resistance, which involve SOCS3, PTP1B, IKK/NF-kB, MyD88, and ER stress (Bence et al., 2006; Howard and Flier, 2006; Kievit et al., 2006; Kleinridders et al., 2009; Zhang et al., 2008) . The current research demonstrated that chronic nutritional excess suppresses OXT release to promote obesity development, and more importantly, Syt4 is identified as the mediator for this dysregulation and hence a molecular target to prevent/ reverse the pathogenesis of obesity. Such potentials of Syt4 were verified in animals by the current research showing that Syt4 inhibition was sufficient to prevent or reverse obesity. Notably, the catabolic effect of Syt4 inhibition on body weight in lean animals was modest, reflecting only a ''miniature'' level of negative energy balance; such a small quantity of negative energy balance is insufficient to cause deleterious effects on health, but accumulatively is sufficient to prevent or treat obesity. Thus, in addition to OXT analogs, developing Syt4 modulators could be another avenue for targeting the Syt4-OXT pathway to combat obesity and related diseases.
EXPERIMENTAL PROCEDURES
Animals and Phenotyping C57BL/6 mice were purchased from Jackson Laboratory. Syt4 À/À mice were previously described (Ferguson et al., 2000a) and backcrossed into C57BL/6 for more than five generations. All mice were housed in standard conditions. HFD was from Research Diets, Inc. The Institutional Animal Care and Use Committee approved all the procedures. Mouse body weight was regularly measured and food intake was determined on a daily basis by individual housing. For pair feeding, individually housed mice were provided daily with a defined amount of food, which was based on mouse group with lower ad libitum food intake prior to pair feeding. Mice that did not consume the whole amount of supplied food were excluded from the final analysis. Energy expenditure was determined using metabolic chambers (Columbus Instrument, Inc.) at DRTC core facility of Albert Einstein College of Medicine. For the glucose tolerance test (GTT), overnight-fasted mice were IP injected with glucose (2 g/kg body weight). Blood glucose was measured using Glucometer Elite (Bayer). Blood insulin and leptin were measured using ELISA kits (Crystal Chem.). Serum OXT levels were measured using Oxytocin EIA kit (Assay Design).
Third Ventricle Cannulation and Animal Treatment As previously described (Zhang et al., 2008) , an ultraprecise small animal stereotactic apparatus (Kopf Instruments) was employed to implant a guide cannula into the third ventricle of anesthetized mice at the midline coordinates of 1.8 mm posterior to the bregma and 5.0 mm below the skull surface. Mice were allowed $1-2 weeks for postsurgical recovery. Individually housed mice received OXT injection (Bachem California, Inc.) via preimplanted cannula.
Lentiviruses and Intra-PVN Injection Lentiviral vectors using mouse OXT gene cassette (Zhang et al., 2002) to direct OXT neuron-specific expression of Flag-tagged Syt4 or GFP were created as previously described (Zhang et al., 2008) . Briefly, DNA of mouse OXT gene cassette (AI-03) was provided by Dr. H. Gainer (Zhang et al., 2002) , and the translation start of exon I was mutated and inserted with Flag-tagged Syt4 or GFP cDNA in the truncated exon III. Lentiviral shRNA against mouse OXT or Syt4 and the matched control lentiviral vector were purchased from Sigma. Lentiviruses were produced from HEK293T cells through cotransfection of target plasmids with their packaging plasmids using Ca 3 (PO 4 ) 2 . Lentiviruses were purified by ultracentrifugation. As previously described (Zhang et al., 2008) , an ultraprecise stereotax was employed to bilaterally inject lentiviruses into the PVN at the coordinates of 0.85 mm posterior to the bregma, 0.15 mm lateral to the midline, and 4.8 mm below the skull surface.
Ex Vivo OXT Release Test
The protocol has been described previously (Jin et al., 2007) . Briefly, the PVN slices were dissected from the hypothalamus. In some experiments, the PVN slices were cut into small pieces at the size of $0.5 mm. The PVN slices were immediately incubated in Locke's solution constantly supplied with 95% O 2 and 5% CO 2 at 37 C. The solution was changed every 5 to 10 min during the 60 min experimental period. An aliquot of Locke's solution was collected to measure the basal levels of OXT release. Depolarization was induced during the final 5 to 10 min by adding KCl to Locke's solution at a final concentration of 70 mM, and an aliquot of Locke's solution was collected to measure KCl-stimulated release of OXT. PVN slices were also collected in some experiments, washed, and lysated for the measurement of tissue OXT content. Oxytocin EIA kit (Assay Design) was used to determine the OXT levels in the solution and tissues.
Heart Perfusion and Brain Immunostaining
Mice under anesthesia were trans-heart perfused with 4% PFA, and brains were removed, postfixed in 4% PFA for 4 hr, and infiltrated with 20%-30% sucrose. Brain sections (20 mm thickness) were made using a cryostat at -20 C. Fixed brain sections were blocked with serum of the appropriate species, penetrated with 0.2% Triton X-100, and treated with primary antibodies including rabbit anti-Syt4 (Synaptic Systems), mouse anti-NeuN (Chemicon), guinea pig anti-OXT, and anti-AVP (Peninsula Lab) IgGs, and followed by either a reaction with Alexa Fluor 488 or 555 secondary antibody (Invitrogen) or a reaction using an ABC kit (Vector Lab). Control IgGs of the appropriate species were used as negative controls. A light microscope was used to detect color staining, and a confocal microscope, to detect fluorescence.
Immunogold Labeling and Electron Microscopy
Mice under anesthesia were trans-heart perfused with 1% PFA and 1% glutaraldehyde, and tissues were isolated, postfixed, dehydrated, embedded in London Resin White, and sectioned at 100 nm. For immunogold labeling, tissue sections on nickel grids were quenched, blocked, and incubated with rabbit anti-Syt4 antibody and guinea pig anti-OXT antibody overnight at 4 C, followed by incubation with gold particle (size: 10 nm or 20 nm)-conjugated secondary antibodies (Ted Pella) for 2 hr at room temperature. Sections were poststained with uranyl acetate and lead citrate, examined on an electron microscope (Hitachi 7500), and imaged using AMT digital imaging equipment.
Quantitative RT-PCR Total RNA from the homogenized tissue samples was extracted using TRIzol (Invitrogen). Complementary DNA was synthesized using the Advantage RTfor PCR kit (Clontech). PCR amplification of Syt4 mRNA was quantified using SYBRÒGreen PCR Master Mix (Applied Biosystems). Results were normalized against the expression of house-keeping genes including TATA box-binding protein (TBP) or b-actin.
Statistical Analyses
Two-tailed Student's t tests were used for two-group comparisons. ANOVA and appropriate post hoc analyses were used for comparisons of more than two groups. Data were presented as mean ± SEM. p < 0.05 was considered statistically significant.
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